|Benfotiamine Catalog No.GC15949|
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
|Chemical Name||S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate|
|Solubility||<4.66 mg/mL in DMSO, <2.83 mg/mL in EtOH, <2.3 mg/mL in H2O||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1); an antioxidant dietary supplement.IC50 value:Target: Benfotiamine, the lipid-soluble thiamine derivative used as a treatment for diabetic neuropathy, can inhibit three major pathways(the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG) protein kinase C (PKC) pathway）of hyperglycemic damage and prevent experimental diabetic retinopathy. Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1) for treating sciatica and other painful nerve conditions. More effective at increasing thiamin levels in blood and tissues than water-soluble salts like the previous vitamin B1.
. Tarallo S, Beltramo E, Berrone E, Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol. 2012 Dec;49 Suppl 1:141-51.
. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway:Evidence from clinical studies. Diabetes Obes Metab. 2012 Dec 26.
. Hurt JK, Coleman JL, Fitzpatrick BJ, et al. Prostatic acid phosphatase is required for the antinociceptive effects of thiamine and benfotiamine. PLoS One. 2012;7(10):e48562.
. Hans-Peter Hammes, Xueliang Du, Diane Edelstein, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 2003, 9, 294 - 299
. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. International Journal of Clinical Pharmacology and Therapeutics, 1996, 34(2):47-50